Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Clinics in Dermatology|June 29, 2013
Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversiesEleonora Ruocco, Vincenzo Ruocco, Maria Lina Tornesello, et al.Clinics in Dermatology|June 22, 2020
Blemished noses in the art of three masters: Ghirlandaio, Rembrandt, and WarholTaha Osman Mohammed, Shahzeb Hassan, Noor Hamideh, et al.International Journal of Dermatology|June 27, 2006
Quinine sulfate inhibits invasion of some bacterial skin pathogensRonni Wolf, Maria Antonietta Tufano, Vincenzo Ruocco, et al.Dermatology Online Journal|September 4, 2003
Quinine sulfate and HSV replicationRonni Wolf, Adone Baroni, Rita Greco, et al.Journal of the American Academy of Dermatology|November 14, 2006
Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trialLawrence Charles Parish, Joseph Lucius Jorizzo, John Jeffrey Breton, et al.Annals of Clinical Microbiology and Antimicrobials|November 20, 2002
Quinine sulfate and bacterial invasionRonni Wolf, Adone Baroni, Rita Greco, et al.Journal of Travel Medicine|December 14, 2005
Quinine sulfate inhibits invasion of Salmonella typhimurium and Shigella flexneri: a preliminary studyRonni Wolf, Elena Grimaldi, Giovanna Donnarumma, et al.Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trialsLinda F Stein Gold, Lawrence Charles Parish, Tracey Vlahovic, et al.Journal of Drugs in Dermatology : JDD|October 5, 2011
A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea crurisLawrence Charles Parish, Jennifer L Parish, Hirak B Routh, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.Pageof 21